All Oncology articles – Page 13
-
ArticleAdvancing CAR-T therapy: how CD5 modulation is shaping cancer treatment
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
-
ArticlePatient-centred oncology: transforming drug development
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
-
NewsKetogenic diet and a new cancer drug starves pancreatic cells
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
-
NewsLargest multi-omics study of colorectal cancer to date
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
-
NewsMelanoma: predicting immunotherapy-induced side effects
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
-
NewsType 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
-
ArticleOut of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes ...
-
NewsProstate cancer: delaying resistance to hormone therapy
Researchers have developed a new form of immunotherapy that could provide a longer life expectancy to men with prostate cancer.
-
News
Improving the effectiveness of immunotherapy for glioblastoma
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
-
ArticleHow mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
-
ArticleSupercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
-
ArticleTranslating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming ...
-
NewsThe role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
-
NewsTreating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
-
NewsSmall molecule inducers of trained immunity found
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
-
ArticleLiquid biopsy helps advance oncology drug development
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
-
NewsThe emergence of targeted alpha therapy for glioblastoma
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
-
ArticleCould illuminating the surfaceome help find new targeted cancer therapies?
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface ...
-
ArticleHow MMR-deficient colorectal cancers regulate their growth
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
-
NewsStudying the epigenetic profile of beta cells in insulinoma
Researchers found that tumour beta cells lose their repression marks and express elevated levels of oncogenes.